Katherine A. High, MD of Spark Therapeutics, presents a press briefing on Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Mean Factor IX Activity Levels of >30% without Immunosuppression at the 58th ASH Annual Meeting in San Diego, CA.
Gene Therapy Development in Hemophilia
